Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3521 | Saliva-based testing Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The primary objective of this early Phase 1 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.
Description: An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Measure: Percentage of Participants with at Least 1 Solicited Injection Site Adverse Event Time: Up to ~5 days after vaccinationDescription: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Measure: Percentage of Participants with at Least 1 Solicited Systemic Adverse Event Time: Up to ~14 days after vaccinationDescription: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Measure: Percentage of Participants with at Least 1 Unsolicited Adverse Event Time: Up to ~28 days after vaccinationDescription: A serious adverse event is "life threatening," requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity and is a congenital anomaly/birth defect.
Measure: Percentage of Participants with at Least 1 Serious Adverse Event Time: Up to ~365 days (±14 days) after vaccinationDescription: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Measure: Percentage of Participants who Discontinued Study Treatment due to an Adverse Event Time: Up to ~365 days (±7 days) after vaccinationDescription: A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason.
Measure: Percentage of Participants with at Least 1 Medically Attended Adverse Event Time: Up to ~365 days (±14 days) after vaccinationDescription: Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.
Measure: Geometric Mean Titers for Serum Neutralizing Antibodies (nAb) as Measured by Plaque Reduction Neutralization Test (PRNT): All Panels Time: Day 29Description: Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.
Measure: Geometric Mean Concentration of Total Anti-Spike Immunoglobulin G (IgG) Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA): All Panels Time: Day 29Description: Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.
Measure: Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PRNT: Panels A,B, I and J Time: Day 85Description: Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.
Measure: Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels A,B, I and J Time: Day 85Description: Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.
Measure: Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PRNT: Panels K and L Time: Day 197Description: Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.
Measure: Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels K and L Time: Day 197Description: Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.
Measure: Geometric Mean Titers for Serum nAb as Measured by PRNT Time: Panels C-E and G-H: Days 1, 15, 29, 57, 85, 115, 211, and 365; Panels A,B, I and J: Days 1, 15, 29, 57, 71, 85, 115, 211, and 422; Panels F, K and L: Days 1, 15, 29, 85, 169, 197, 365 and 534Description: Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.
Measure: Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA Time: Panels C-E and G-H: Days 1, 15, 29, 57, 85, 115, 211, and 365; Panels A,B, I and J: Days 1, 15, 29, 57, 71, 85, 115, 211, and 422; Panels F, K and L: Days 1, 15, 29, 85, 169, 197, 365 and 534Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports